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ABSTRACT
The introduction of checkpoint inhibitors represents a major advance in cancer 
immunotherapy. Some studies on checkpoint inhibition demonstrate that combinatorial 
immunotherapies with secondary drivers of anti-tumor immunity provide beneficial 
effects for patients that do not show a strong endogenous immune response. CD40-
activated B cells (CD40B cells) are potent antigen presenting cells by activating and 
expanding naïve and memory CD4+ and CD8+ and homing to the secondary lymphoid 
organs. In contrast to dendritic cells, the generation of highly pure CD40B cells is simple 
and time efficient and they can be expanded almost limitlessly from small blood samples 
of cancer patients. Here, we show that the vaccination with antigen-loaded CD40B cells 
induces a specific T-cell response in vivo comparable to that of dendritic cells. Moreover, 
we identify vaccination parameters, including injection route, cell dose and vaccination 
repetitions to optimize immunization and demonstrate that application of CD40B cells 
is safe in terms of toxicity in the recipient. We furthermore show that preventive 
immunization of tumor-bearing mice with tumor antigen-pulsed CD40B cells induces 
a protective anti-tumor immunity against B16.F10 melanomas and E.G7 lymphomas 
leading to reduced tumor growth. These results and our straightforward method of 
CD40B-cell generation underline the potential of CD40B cells for cancer immunotherapy.
INTRODUCTION
A major advance in cancer immunotherapy has been 
the development of checkpoint inhibitors, which show 
clinical efficacy in a variety of advanced malignancies 
[1-4]. Some studies point to the idea that the expression 
of inhibitory ligands, such as CTLA-4 or PD-L1, by the 
tumor represents an adaptive response to tumor-specific 
T cells in the microenvironment [5, 6]. Thus, PD-L1 
expression may indicate the presence of an endogenous 
anti-tumor immunity, while low expression may 
indicate the absence of such a response [7]. Treatment 
with a second driver of anti-tumor immune responses 
was shown to enhance the adaptive induction of the 
checkpoint molecule PD-L1 on tumor cells [7]. Although 
contradictory at first sight, this upregulation of checkpoint 
molecules was critical for the efficacy of the subsequent 
treatment with checkpoint inhibitors and finally resulted in 
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regression of established tumors. Possible other secondary 
inducers of anti-tumor immunity might include cellular 
vaccines or chimeric antigen receptor T cells.
As cellular vaccine, dendritic cells (DCs) have been 
the major object of interest in pre-clinical studies and 
clinical trials over the past decade [8-11]. However, after 
more than 200 clinical studies with DC-based vaccines, 
the response-rate to vaccination has been disappointingly 
low. The recent meta-analysis by Draube et al. included 29 
clinical trials in patients with prostate and renal cell cancer 
and demonstrated a statistically significant association 
between the DC-induced cellular immune response and 
the clinical outcome [9]. However, this meta-analysis also 
identified several challenges and areas of uncertainty: First, 
the ideal DC subtype and methods to generate this subtype in 
sufficiently high purity; second, the optimal injection route 
for migration to the peripheral lymphoid organs; and third, 
the most efficient technique for antigen delivery. The study 
determined two critical factors in the analyzed clinical trials. 
In only ten out of 29 studies the DC purity was determined 
and only in four of those, the DC purity was higher than 80 
%. Moreover, DCs fail to express CD62L, a molecule that is 
essential for homing into the lymph nodes [12].
Although it was initially described that B cells 
induce tolerance rather than an effector immune response 
[13, 14], this effect was shown to be limited to resting 
or lipopolysaccharide (LPS)-activated B cells [15, 16] 
and seems to depend strongly on the strength of B-cell 
activation [17]. In contrast, upon stimulation with the 
CD40 ligand (CD40L) human and murine primary B cells 
develop into potent antigen-presenting cells (APCs) [18]. 
CD40B-activated B cells (CD40B cells) can be expanded 
from small amounts of peripheral blood or splenocytes of 
healthy donors and cancer patients [19, 20] to an almost 
unlimited extend [21]. They upregulate costimulatory and 
MHC molecules and induce naïve and memory CD4+ and 
CD8+ T-cell responses in an MHC-restricted manner [19, 
20, 22-25]. In contrast to DCs, CD40B cells express all 
relevant homing molecules, including CD62L, and were 
shown to migrate to the secondary lymphoid organs in vivo 
in healthy and tumor-bearing mice [26, 27]. In vivo, CD40B 
cells have been demonstrated to induce anti-tumor immunity 
in a murine breast cancer model [28] and a specific T-cell 
response in spontaneous cancer in dogs [29, 30].
Recently, the major obstacle for the use of CD40B 
cells in a clinical trial in cancer patients has been overcome 
by the development of a soluble human CD40 ligand 
that can be produced in a GMP-conform manner and induces 
both strong activation and expansion of human B cells [31].
In the present study, we identified the optimal 
vaccination parameters for the induction of a specific 
T-cell response by use of CD40B cells and showed that 
administration of very high doses of CD40B cells does not 
induce toxicity in vivo. Treatment of mice with peptide-
loaded CD40B cells led to anti-tumor immunity resulting 
in reduced growth of two different tumor entities.
RESULTS
CD40L stimulation of murine splenocytes results 
in the acquisition of an APC phenotype
Optimized culture conditions for activation of 
murine splenocytes via CD40L stimulation as described 
in Figure 1A resulted in the selective proliferation and 
expansion of CD19+ B cells. Over the course of the 14-
day culture period B-cell purity steadily increased from ~ 
45 % to ~ 98 % (Figure 1B). Treatment with cyclosporine 
A efficiently inhibited growth of CD3+ T cells. On day 14, 
CD40B cells were analyzed for the expression levels of 
several surface markers defining their antigen presenting 
phenotype. CD40B cells highly upregulated the activation 
markers CD80, CD86, MHC I and MHC II from day 0 to 
day 14 (Figure 1C) and significantly downregulated the 
expression of IgD (Figure 1D). The percentage of CD138+ 
plasma cells increased, while the percentage of IgG+ or 
IgM+ B cells did not change significantly (Figure 1D).
CD40B cells induce proliferation and activation 
of CD4+ and CD8+ T cells
To study the antigen-presenting function of murine 
CD40B cells, their ability to stimulate a T-cell response 
in vitro was investigated. Peptide-pulsed APCs from 
C57BL/6 (B6) mice were co-cultured together with CD4+ 
or CD8+ T cells from BALB/C mice. CD40B cells were 
activated for 7 or 14 days in the CD40L culture. Bone-
marrow derived DCs served as alternative source of 
APCs and positive control in mixed-lymphocyte reactions 
(MLRs). Maturation of DCs with LPS or CD40L was 
tested to cover the heterogeneity of DC subsets [32, 33]. 
Mature DCs highly upregulated the activation markers 
CD80, CD83, CD86 and IAb (data not shown).
T-cell activation and proliferation was determined 
by flow cytometry. In an APC-to-T cell ratio of 1:1, both 
LPS- and CD40L-matured DCs induced high proliferation 
and activation of CD4+ (Figure 2A) and CD8+ T cells 
(Figure 2B). In all tested APC-to-T cell ratios, LPS-matured 
DCs were less potent in the induction of a CD4+ or CD8+ 
T-cell response than CD40L-matured DCs (Figure 2C and 
2D, respectively). As expected from their expression of 
activation markers, CD40B cells were highly potent in the 
initiation of an alloreactive CD4+ or CD8+ T-cell response 
by inducing both proliferation and activation of the T cells 
(Figure 2A and 2B). However, even in high B-to-T cell ratios 
they induced less proliferation than LPS- or CD40L-matured 
DCs. While DCs induced four to five rounds of division in 
CD4+ and CD8+ T cells, CD40B cells only induced two to 
three rounds of division. Interestingly, at high APC-to-T 
cell ratios, CD40B cells that were activated for 7 days only 
(CD40B d7) induced significantly more proliferation of 
CD4+ T cells than CD40B cells that were activated for 14 
days (CD40B d14) (Figure 2E). In contrast, the proliferation 
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of CD8+ T cells was higher when cultured together with 
CD40B d14 (Figure 2F). With a decreasing CD40B-to-T cell 
ratio the proliferation of T cells decreased. This effect was 
also observed in DC cultures, but less pronounced.
Adoptive transfer of CD40B cells does not lead 
to toxicity in vivo
Toxic side effects are a critical point when 
considering adoptive transfer of immune cells for 
the clinical application. To rule out the possibility of 
toxic side effects from adoptive transfer of CD40B 
cells, we challenged B6 mice with pure CD40B cells 
in three different injection routes, i.e. intraperitoneal 
(ip.), intravenous (iv.) and subcutaneous (sc.). In lack 
of a murine soluble CD40L that induces both strong 
activation and expansion of murine B cells, CD40B cells 
were generated with CD40L-expressing feeder cells as 
described in Figure 1A. However, this activation system 
is not clinically applicable in studies with humans. To 
address long-term toxicity, twice per week over a period 
of five weeks we injected high doses of CD40B cells, 
i.e. 1 x 106 cells/injection equal to 40 x 106 cells/kg. 
Injection of PBS buffer served as negative control. After 
Figure 1: B cells develop an APC-phenotype upon CD40L activation. A. In the optimal CD40-culture system splenocytes are 
co-cultured together with CD40L-expressing HeLa cells in the presence of IL-4, ß-mercaptoethanol (ß-ME) and Cyclosporin-A (CsA). 
Cells are recultivated every 3 days and analyzed or used for experiments after 14 days. B. At every recultivation day the relative increase 
was assessed by normalizing the relative growth to the percentage of CD3+ and CD19+ cells in the culture as determined by flow cytometry. 
(n=5). CD40B cells were phenotypically characterized on day 14 by measuring C. the mean fluorescence intensity (MFI) of the activations 
markers CD80 and CD86 and the MHC molecules I and II D. or the expression of different immunoglobulin subtypes and CD138. MFI 
values on day 14 were normalized to values on day 0. Significant differences calculated by Student’s t-test are indicated by an asterisk: * p 
≤ 0.05, ** p ≤ 0.01, ns = not significant. Histograms show representative analyses compared to an unstained control (filled line). Results of 
five independent experiments are shown.
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Figure 2: CD40B cells induce T-cell proliferation and activation in allogenic MLRs. A-B. For negative controls (Neg. 
Control) T cells were incubated without stimulating APCs. Dendritic cells were stimulated with LPS (DC LPS) or the CD40L (DC CD40). 
CD40B cells were used on day 7 (CD40B d7) or day 14 (CD40B d14) of activation. Left column= Typical sequential halving of CFSE 
fluorescence intensity with each generation was detected by flow cytometry. Right column= CFSE intensity, which was accompanied by 
upregulation of CD25 expression was detected by flow cytometry. One representative experiment out of 8 is shown. A. CD3+ CD4+ T cells 
from BALB/C mice were cocultured with the indicated APCs. B. CD3+ CD8+ T cells from BALB/C mice were cocultured with the indicated 
APCs. C. CD3+ CD4+ T-cell proliferation at various APC-to-T cell ratios in allogenic MLRs with either DC LPS or DC CD40 as APCs. 
D. CD3+ CD8+ T-cell proliferation at various APC-to-T cell ratios in allogenic MLRs with either DC LPS or DC CD40 as APCs. E. CD3+ 
CD4+ T-cell proliferation at various APC-to-T cell ratios in allogenic MLRs with either CD40B d7 or CD40B d14 as APCs. F. CD3+ CD8+ 
T-cell proliferation at various APC-to-T cell ratios in allogenic MLRs with either CD40B d7 or CD40B d14 as APCs. Mean values ± SD of 
eight independent experiments are shown. Significant differences calculated with Student’s t-test are indicated by an asterisk: * p ≤ 0.05, 
** p ≤ 0.01, *** p ≤ 0.001.
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five weeks of further observation, mice were analyzed 
for changes in behavior, weight or survival. In all three 
injections routes we could not detect any differences 
compared to controls (Figure 3A). Furthermore, we 
performed histo-pathological analyses of clinical 
relevant organs (Figure 3B) and screened secondary 
lymphoid organs for rejection reactions (Figure 3C and 
3D). A detailed examination of heart, lung liver, spleen 
and kidney sections revealed no abnormal lymphocytic 
infiltration, structural tissue injury or other indications of 
inflammation (Figure 3B). Spleens (Figure 3C) as well as 
mesenteric and inguinal lymph nodes (Figure 3D) were 
analyzed for changes in the lymphocyte subsets by flow 
cytometry. No significant differences were observed in the 
percentage of B220+ B cells or CD3+ T cells and the T-cell 
subpopulations CD4+ T cells and CD8+ T cells between 
controls and CD40B cell-treated mice. Acute toxicity was 
assessed by treating mice once with a very high dose of 
CD40B cells, i.e. 1 x 107 cells/injection equal to 40 x 107 
cells/kg. No abnormal changes in organ sections or flow 
cytometry analyses of lymphoid organs were observed 
(data not shown). In comparison, in clinical trials with 
DC-based vaccines in patients with prostate and renal cell 
cancer average doses of 0.06 – 0.13 x 106 cell/kg were 
administered [34-42] with the lowest dose of 0.0075 x 106 
cell/kg [43] and the highest dose of 1.5 x 106 cell/kg [44]. 
In a study with dogs with spontaneous cancer 1-5 x 106 
CD40B cells were injected per dog, which equals 0.03-
0.15 x 106 cells/kg [30]. Our data therefore demonstrate 
the safety of CD40B-cell administration for in vivo 
adoptive transfer.
CD40B cells induce an antigen-specific CD8+ 
T-cell response in vivo
Since CD40B cells showed the capacity to induce 
T-cell responses in vitro, we tested their antigen-presenting 
function in vivo. In addition, we evaluated different 
vaccination parameters, including the injection route, the 
cell dose and injection intervals. Induction of specific 
CD8+ T-cell responses was assessed using two different 
functional assays. First, the direct cytolytic activity was 
determined by measuring the specific lysis of peptide-
pulsed target cells in spleens of APC-vaccinated B6 
mice. Second, the percentage of IFN-γ producing CD8+ T 
cells was analyzed by flow cytometry in spleens of APC-
vaccinated mice. To increase signal strength OT-I mice 
were used in this experiment instead of B6 mice.
Significant differences in the induction of specific 
lysis were observed when testing different injection 
routes (Figure 4A) by vaccinating mice once with 1 x 
106 CD40B cells. The cytolytic activity of CD8+ T cells 
was significantly higher in mice that were vaccinated ip. 
than in mice that were vaccinated sc. or iv. No significant 
differences were observed in the percentage of IFN-γ 
CD8+ T cells between the different injection routes. 
However, the percentage of IFN-γ producing CD8+ T cells 
was higher in mice that were vaccinated with peptide-
pulsed CD40B cells than in mice that were treated with 
unpulsed CD40B cells or peptide alone. Henceforward, in 
all subsequent experiments mice were vaccinated ip.
We next determined the optimal cell dose for 
vaccination. A dose-dependent effect of vaccinations with 
CD40B cells was identified. An increase of the cell dose 
from 1 x 105 cells/injection to 1x 106 cells/injection led to 
a significant increase in the induction of specific lysis and 
the production of IFN-γ in CD8+ T cells (Figure 4B). Even 
though a further increase of cell dose 1x 106 cells/injection 
to 1x 107 cells/injection did not result in significant 
differences in the specific lysis it led to an increase in the 
production of IFN-γ CD8+ T cells.
To determine the effect of varying vaccination 
intervals, mice received either two or three injections 
of 1 x 106 cells ip. in an interval of seven days. LPS- or 
CD40L-stimulated DCs were included into the vaccination 
experiments to compare their antigen-presenting function 
to that of CD40B cells. Following a second booster 
vaccination the percentage of specific lysis increased 
from 83.7 % ± 13.4 with one booster vaccination to 99.8 
% ± 0.3 with two booster vaccinations (Figure 4C). This 
effect was not reflected in an increase in IFN-γ production. 
The levels of specific lysis and IFN-γ CD8+ T cells were 
comparable in mice that were vaccinated with LPS- or 
CD40L-matured DCs.
The induced T-cell response after vaccination 
with protein-pulsed APCs was characterized by staining 
CD3+ T cells for the presence of ovalbumin (OVA)-
peptide specific CD8+ T cells (Figure 4D). Mice that were 
vaccinated with CD40B cells showed significantly higher 
percentages of OVA-specific CD8+ T cells than negative 
and positive controls, but lower percentages than mice 
that were treated with mature DCs. No increase in CD25 
expression was observed (data not shown).
Treatment with CD40B cells induces anti-tumor 
immunity in vivo
The effect of a preventive treatment with CD40B 
cells on tumor growth was determined by challenging 
mice with B16.F10 melanomas or E.G7 lymphomas. 
To determine the migratory behavior after ip. injection, 
CD40B cells that were generated from luciferase+ mice 
were injected into E.G7 tumor-bearing B6 mice and their 
migration was tracked using the IVIS system. CD40B cells 
showed the expected migratory pattern (Figure 5A) [26]. 
One and five days after ip. injection luciferase+ CD40B 
cells were detected in the spleen and the tumor-draining 
lymph nodes, but not the tumor itself (Figure 5B). To 
examine the effect of peptide/protein-loaded CD40B cells 
in a preventive vaccination approach for tumor targeting, 
106 peptide/protein-pulsed APCs were injected into B6 
mice ip. three times in an interval of seven days. On day 
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Figure 3: Immunization with CD40B cells does not lead to in vivo toxicity. B6 mice were challenged with either CD40B cells 
or PBS alone as negative control in three different routes; i.e. intravenous (iv), intraperitoneal (ip) or subcutaneous (sc). Five weeks after 
CD40B cell injection they were analyzed for indications of toxicity. A. The weight of the mice and the survival over a period of ten days 
were documented. Mean values ± SD of four independent experiment with five mice per group are shown. B. H&E stained sections of 
heart, lung, liver, spleen and kidney were analyzed. Representative pictures out of four independent experiments are shown. C. Spleens of 
mice were analyzed by flow cytometry for B220+ B cells or CD3+ T cells and the T cell subpopulations CD4+ and CD8+ cells. Mean values 
± SD of four independent experiment with five mice per group are shown. D. Mesenteric and inguinal lymph nodes (LN) of mice were 
analyzed by flow cytometry for B220+ B cells or CD3+ T cells and the T-cell subpopulations CD4+ and CD8+ cells. Mean values ± SD of 
four independent experiment with five mice per group are shown.
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Figure 4: Immunization with CD40B cells induces specific T-cell responses in vivo. A-C. Left column = Specific lysis was 
determined by injecting 1 x 107 target cells labeled with different amount of CFSE ip. into vaccinated B6 mice 4 days after the last 
immunization. The ratio of OVA-pulsed target cells versus unpulsed target cells was determined by flow cytometry one day later and 
the specific lysis was calculated. Right column = Production of IFN-γ was determined by flow cytometry after restimulating purified 
lymphocytes of vaccinated OT-I mice with peptide. Mean values of frequencies of restimulated cells were normalized to corresponding 
values of unstimulted cells. Mice were immunized with OVA-peptide pulsed CD40B cells (CD40B +) or unpulsed CD40B cells (CD40 -). 
Negative controls (Neg. Control) were immunized with PBS+IFA alone, positive controls (Pos. Control) were immunized with Peptide 
+ CpG + IFA. Bar charts show mean values ± SD of four independent experiments with three mice per group. Significant differences 
calculated with Student’s t-test are indicated by an asterisk: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. A. Three different injection routes were 
tested for vaccination with peptide-pulsed CD40B cells; i.e. intravenous (iv), intraperitoneal (ip) or subcutaneous (sc). B. Different cell 
numbers were tested for vaccination with peptide-pulsed CD40B cells; i.e. 1 x 105, 1 x 106 and 1 x 107. C. Different vaccination intervals 
were tested for vaccination with peptide-pulsed CD40B cells; i.e. injection on day 0 and 7 (2 inject.) or on day 0, 7 and 14 (3 inject.). 
Peptide-pulsed DCs stimulated with LPS or CD40L served as additional control. D. CD3+ CD8+ T-cells from spleens of vaccinated B6 mice 
were stained for the presence of OVA peptide-specific T-cells. Bar charts show mean values ± SD of four independent experiments with 
three mice per group. Significant differences calculated with Student’s t-test are indicated by an asterisk: * p ≤ 0.05, ** p ≤ 0.01.
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21, immunized mice were challenged with 1 x 106 B16.F10 
melanoma cells (Figure 5C) or 0.4 x 106 E.G7 lymphoma 
cells (Figure 5D). Tumor growth of B16.F10 melanomas 
in mice that were treated with 1 x 106 CD40B cells/
injection was significantly reduced compared to negative 
controls on day 11, but only when cells were pulsed with 
B16 melanoma-specific TRP2-peptide (Figure 5C). An 
increase of the cell dose 1 x 107 CD40B cells/injection 
did not result in a significant difference in tumor growth 
compared to the lower cell dose. Tumors in mice that were 
treated with LPS- or CD40L-stimulated DCs grew slower 
than in CD40B-cell treated mice. Two of three mice that 
were treated with LPS-stimulated DCs stayed tumor free 
until day 13 after tumor challenge (data not shown).
For the E.G7 lymphoma model, mice were 
vaccinated with OVA-protein pulsed APCs. Only the 
optimal vaccination conditions for CD40B cells and 
dendritic cells, i.e. 106 CD40B cells and LPS-activated 
DCs, were chosen for this experiment. E.G7 tumors grew 
slower than B16.F10 melanomas in general and negative 
controls survived until day 20 (Figure 5D). At this time 
point, APC-treated mice showed a significantly reduced 
tumor growth compared to negative controls. Mice that 
were treated with CD40B cells or DCs survived until 
day 28 and there was no significant difference in tumor 
volume.
Figure 5: Vaccination with CD40B cells induces anti-tumor immunity in vivo. A. Expression of the homing molecules 
CXCR4, CXCR5, CCR7 and CD62L in CD40B cells from luciferase+ mice on day 14 was compared to the expression before stimulation. 
Histograms show representative analyses of four independent experiments compared to an unstained control (filled line). B. CD40B cells 
from luciferase+ mice were injected intraperitoneally into E.G7 tumor-bearing B6 mice. Homing behavior was measured in the IVIS system 
on day 1 or day 6 after injection. Representative pictures of five independent experiments with three mice per group are shown. C. B6 
mice were treated with 1 x 106 or 1 x 107 TRP2-peptide pulsed CD40B cells (CD40Bs +) or unpulsed CD40B cells (CD40Bs -) three times 
in an interval of seven days before challenging them with B16.F10 melanomas 7 days after the last vaccination. Alternatively, mice were 
vaccinated with 1 x 106 LPS or CD40L stimulated DCs. Injection of PBS alone served as negative control (Neg. Control). Tumor growth 
was assessed daily. One representative experiment out of two independent experiments with three mice per group is shown. Significant 
differences calculated with paired Student’s t-test are indicated by an asterisk: ** p ≤ 0.01, *** p ≤ 0.001. D. B6 mice were treated with 1 x 
106 OVA-protein pulsed CD40B cells (CD40Bs +) three times in an interval of seven days before challenging them with E.G7 lymphomas 
7 days after the last vaccination. As positive control, mice were vaccinated with 1 x 106 LPS stimulated DCs. Injection of PBS alone served 
as negative control (Neg. Control). Tumor growth was assessed daily. One representative experiment of four independent experiments 
with three mice per group is shown. Significant differences calculated with paired Student’s t-test are indicated by an asterisk: ns = not 
significant, *** p ≤ 0.001.
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DISCUSSION
Our results presented in this study support the 
potential of CD40B cells for cancer immunotherapy 
and underline the importance of the optimal vaccination 
strategy for cellular immunotherapy.
So far contradicting results were described about the 
antigen-presenting capacity of CD40B cells in vivo. The 
discrepancy between our own results and the studies that 
reported weak T-cell responses by CD40B-cell vaccination 
can be explained by the different setup of the studies. Lee 
et al. [45] and Guo et al. [46] used monoclonal anti-CD40 
antibodies to activate their B cells, which did not result 
in the same elevated expression levels of costimulatory 
and MHC molecules that we observed in our study by 
using CD40L-expressing feeder cells for the activation 
of B cells. This effect is probably due to higher cross-
linking capacity of membrane-bound CD40L [31, 47, 48]. 
Our results are supported by a study in 4T1 breast cancer 
tumors [28] that demonstrated an induction of a specific 
T-cell response by CD40B-cell vaccination in vivo and a 
reduced appearance of metastases. It was also suggested 
that peptide-pulsing of CD40B cells is not sufficient for 
antigen presentation and the induction of a T-cell response 
[28, 46]. However, failure of peptide-pulsed B cells to 
induce a specific T-cell response probably also resulted 
from insufficient activation of B cells and the failure 
to upregulation costimulatory molecules. Our results 
obtained here clearly demonstrate that peptide-pulsing 
of highly activated CD40B cells is indeed sufficient to 
induce an effective immune response. We thereby offer 
a simpler method for the development of efficient APCs, 
since other methods for stable presentation of antigen by 
B cells is critical in a human application. Furthermore, 
we showed that the in vivo induction of the CD8+ T-cell 
response depends on the injection route and the dose of 
injected cells. It seems that even at low numbers under 
optimal vaccination conditions and after strong CD40L-
activation, CD40B cells overcome inhibitory mechanisms 
by the tumor. This idea is also supported by a study on 
tumor-mediated immune suppression of CD40B cells. 
Phenotype, migratory potential and antigen-presenting 
function of human CD40B cells were shown to be resistant 
to interleukin-10, TGF-β and VEGF [48].
Under optimal vaccination conditions, CD40B cells 
showed similar or less effect on tumor growth than mature 
DCs. Nevertheless, DCs should not simply be identified as 
superior APCs for cancer immunotherapy. Some aspects 
make the comparison of two such very fundamentally 
differing cell types difficult. DCs possess a 4.5 times 
higher surface area than CD40B cells (data not shown) 
and therefore express more costimulatory and MHC 
molecules on their surface. Since both DCs and CD40B 
cells were shown to make contact with more than one T 
cell at a time [26], a higher surface area might lead to an 
advantage in antigen presentation when the same number 
of APCs are used. To truly compare the two cell types, 
cell numbers adjusted for surface size should be used. 
Moreover, maturation of DCs by LPS might not be the 
optimal stimulus, since LPS is a known to induce a septic 
shock in humans and mice [49]. In addition, CD40B cells 
and DCs were administered in different injections routes to 
apply both cell types under their most optimal conditions.
Similar to DCs, B cells are able to take up antigen 
by fluid phase pinocytosis. However, their strength lies in 
uptake of a specific antigen via the B cell receptor (BCR). 
The BCR has a high affinity for a given antigen and allows 
B cells to concentrate very small quantities of their specific 
antigen resulting in important changes in the antigen 
processing machinery [50]. In contrast, presentation after 
uptake by fluid phase pinocytosis in B cells requires about 
5000 times higher concentrations [51]. Therefore, it might 
be possible to enhance CD40B-cell vaccination by use of 
tumorantigen-specific CD40B cells.
In a study with dogs with spontaneous cancer, one 
dog developed signs of acute systemic reaction. However, 
no long-term complications were monitored [30]. In 
our study, application of CD40B cells even in very high 
cell doses that were 3000 to 6000 times higher than cell 
doses used in clinical DC-based studies or pre-clinical 
CD40B-cell studies proved to be safe without any toxic 
side effects. This is highly relevant since the induction 
of clinical toxicity is still a major problem in current 
cellular immunotherapies [52]. The choice of antigen 
for loading of CD40B cells is of crucial importance and 
should be limited to tumor-specific or tumor-associated 
antigens only. Here, we did not load CD40B cells with 
antigen for toxicity assessment, but mice in tumor control 
experiments showed no signs of autoimmune reaction. 
Additionally, the existence of the clinically approved anti-
CD20 antibody Rituximab offers the option to deplete 
B cells if the induced immune reaction should lead to 
autoimmunity [53].
Taken together, CD40B cells were shown to induce 
anti-tumor immunity even in the low immunogenic model 
B16.F10 that expresses minimal PD-L1 [54]. Active tumor 
antigen-specific vaccination with CD40B cells therefore 
might be a promising combination partner for cancer 
immunotherapy in conjunction with checkpoint inhibitors. 
With regard to the earlier mentioned challenges in cellular 
immunotherapy, CD40B cells with an activated phenotype 
can be easily generated in high purity, a clinical applicable 
injection route results in strong T-cell responses and B 
cells take up whole protein antigen by simple protein 
pulsing. CD40B cells therefore might induce weaker 
immune responses in vivo than mature DCs, but their use 
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with the ethical standards and according to national and 
international guidelines and has been approved by the 
authors’ institutional review board.
Blood samples and mice
C57BL/6 mice (designated as B6) and BALB/C 
mice were obtained from JANVIER Labs. Luciferase+ 
C57BL/6 mice were kindly provided by Prof. Dr. Robert 
Zeiser (Laboratory for Allo-Immunregulation, Department 
for Internal Medicine I, University Hospital Freiburg, 
Germany). OT-I mice expressing OVA-specific CD8+ T 
cells were obtained from the Jackson Laboratory. Mice 
were housed under specific pathogen-free conditions and 
all animal experiments were approved by the Cologne 
regional animal care committee.
Isolation of lymphocytes
Murine splenocytes were isolated using Pancoll 
density-gradient centrifugation (Pan-Biotech). B cells 
were enriched using positive immunomagnetic selection 
with murine CD19 microbeads (Miltenyi Biotec) 
according to manufacturer’s protocol. Murine T cells 
were purified by negative selection using EasySep Mouse 
T Cell Enrichment Kit (Stem Cell Technologies) according 
to manufacturer’s protocol.
Generation of murine CD40B cells
Murine B cells were activated and expanded using 
the established system of adherent murine epithelial 
cell lines expressing murine CD40L. tmuCD40L HeLa 
feeder cells were kindly provided by Professor Clemens 
Wendtner (Klinikum Schwabing, Munich, Germany). 
Cell culture was performed as described previously [55]. 
Briefly, CD19+ B cells or splenocytes were seeded at a 
density of 1 x 106 cell/ml on lethally irradiated feeder 
cells. Cell passaging of feeder cells was done twice per 
week. B cells were cultured in DMEM medium (Life 
Technologies) supplemented with 580 μg/ml Glutamine, 
10% Fetal-bovine serum, 1 % HEPES, 1 % MEM and 15 
μg/ml gentamicin. 50U/mL of recombinant murine IL-4 
(Immunotools) were freshly added.
Generation of mature dendritic cells
Murine CD34+ progenitor cells were purified 
from bone marrow of hind limbs of B6 mice by positive 
selection with EasySep Biotin Selection Kit (Stem Cell 
Technologies) using an anti-murine CD34-biotinylated 
antibody (Biolegend). The cells were cultivated at a 
concentration of 0.25 x 106 cell/ml in VLE-RPMI medium 
supplemented with 5 % FBS, 50 μM ß-mercaptoethanol 
and 500 U/ml of murine granulocyte macrophage colony-
stimulating factor and 1 U/ml murine IL-4. On days 3, and 
5 of the cultivation period, the medium was replaced. For 
maturation, the medium was supplemented with either 10 
ng/ml LPS (Sigma Aldrich) or 1 μg/ml anti-mouse CD40L 
antibody (clone HM40-3, Acris Antibodies).
Flow cytometry
Cell phenotypes were evaluated using the following 
fluorophore-conjugated antibodies for the indicated 
cell types: B cells with anti-mouse B220, CD19 (Life 
Technologies), CD80, CD86, CD138, IAb, IgD, IgG1, IgM 
and H2Kb (Biolegend); T cells with CD3e, CD4, CD8, 
CD25, CD62L (Biolegend) and SIINFEKL-H2Kb Tetramer 
(Glycotope Biotechnology); DCs with CD11b, CD11c, 
CD80, CD83, CD86 (Biolegend). 0.5x106 cells were 
washed twice with PBS and incubated with antibodies for 
15 min at 4 °C. The data were collected on a Gallios flow 
cytometer (Beckman Coulter) and analyzed using FlowJo 
(Tree Star) or Kaluza (Beckman Coulter) software.
Intracellular staining for INF-γ
Splenocytes from vaccinated mice were purified by 
Pancoll and stimulated with 10 μM OVA-peptide for 4 
hours at 37 °C. Stimulation with Paramethoxyamphetamin 
and Ionomycin served as positive control. Incubation 
was stopped by adding 0.66 μl Golgi-Stop/106 cells (BD 
Biosciences). Cells were stained for surface markers 
before they were fixed with 250 μl Cytofix/Cytoperm 
solution (BD Biosciences). After 20 min incubation, they 
were permeabilized by incubation in 500 ml Perm/Wash 
solution. Ten min later, cells were stained for intracellular 
IFN-γ. Mean values of frequencies of IFN-γ+ CD8+ T cells 
that were restimulated with peptide were normalized to 
corresponding unstimulated samples.
Mixed-lymphocytes reactions
APCs were irradiated once with 26 Gy and then 
mixed at different ratios with CD3+ T cells from spleens 
of BALB/C mice. T cells were stained with the 10 μM 
CFSE. Co-cultures were incubated for 5 days.
In vivo immunization of naïve mice
For positive controls B6 mice were immunized 
with OVA-Protein/IFA solution in addition of 
7 μM immunomodulatory CpG-ODN 2395 
(oligodeoxynucleotide with non-methylated cytosine-
guanine motifs). For immunization in the E.G7 tumor 
model, APCs were exogenously loaded with 10 μM OVA-
protein for 1 hour at 37 °C. For immunization in the B16.
F10 melanoma model, APCs were loaded with TRP-2 
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peptide (aa180-188). For in vivo cytotoxicity assays 
and IFN-γ assays, APCs were loaded with OVA-peptide 
(aa257-264).
In vivo cytotoxicity assay
For in vivo cytotoxicity assays, OVA-peptide 
(aa257-264) pulsed CFSE-labeled target cells were 
injected i.p. into immunized mice on day 21. Twenty-four 
hours later, spleens were removed and analyzed for killing 
of peptide-pulsed target cells. The ratio of unpulsed versus 
pulsed (RatioUP) target cells was determined by dividing 
the percentage of CFSE low cells by the percentage of 
CFSE high cells. Specific lysis was calculated by the 
following formula: % Specific Lysis = (1-(RatioUP 
Negative Control/RatioUP Immunized))*100.
In vivo migration
Murine CD40B cells from luciferase+ mice were 
injected ip. into B6 mice. Detection of luciferase+ B cells 
was performed by injecting 7.5 mg D-Luciferin in 250 ml 
1x PBS i.p. The luciferin was allowed to distribute in the 
mouse for 5 min before mice were narcotized with 1.5-4 % 
Insofluran. Mice were shaved prior to imaging in order to 
minimize interference by the fur. Imaging was performed 
in the Xenogen IVIS 200 (Perkin Elmer). Mice were 
constantly kept under narcosis with 1.5-4 % Insofluran at 
37 °C. Bioluminescence pictures were analyzed with the 
Living Image Software (Perkin Elmer).
Assessment of secondary immunological effects
B6 mice were immunized with 1 x 107 CD40B cells 
i.v., i.p. or s.c. twice per week. Mice were observed for 
changes in behavior and clinical symptoms, i.e. reduced 
food and water intake, reduced activity, difficulties of 
breathing and moving and increased body temperature. 
After five weeks mice were sacrificed, weighted and 
organs analyzed by H&E staining.
Tumor challenge
Tumor cells E.G7 and B16.F10 were kept at a low 
concentration of 1 x 106 cells/ml prior to injection. For 
tumor formation, cells were harvested and resuspended 
at a concentration of 0.4 x 107 cells/ml or 1 x 107 cells/
ml in 1x PBS, respectively. 100 μl were injected s.c. into 
the right flank of immunized or naïve B6 mice. Tumor 
size was determined daily from day 7 after inoculation 
by measuring tumor diameter in two dimensions using a 
vernier caliper. The tumor volume was calculated using 
the following formula: Tumor volume = 0.5 x (length x 
width2) mm. Tumors were allowed to grow for 40 days or 
until one diameter reached a size of 15 mm.
Statistical analysis
Significant differences were calculated by Student’s 
t-test for paired data, ordinary one-way ANOVA or 
ordinary two-way ANOVA were appropriate using 
GraphPad Prism Software. P-values of less than 0.05 
were considered statistically significant and marked with 
asterisks: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p 
≤ 0.0001. Mean values and standard deviations (SD) were 
calculated from at least 3 independent experiments.
ACKNOWLEDGMENTS
We thank Samir-Ghali Tawadros for sharing his 
comprehensive expertise in handling of mice.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
GRANT SUPPORT
The Else-Kröner-Fresenius-Stiftung supported our 
research on CD40B cell-based cancer immunotherapy.
REFERENCES
1. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, 
Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller 
TL, Gilson MM, Wang C, Selby M, et al. Phase I study 
of single-agent anti-programmed death-1 (MDX-1106) in 
refractory solid tumors: safety, clinical activity, pharmaco-
dynamics, and immunologic correlates. J Clin Oncol. 2010; 
28:3167-3175.
2. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman 
JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, 
Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky 
J, et al. Improved survival with ipilimumab in patients 
with metastatic melanoma. N Engl J Med. 2010; 
363:711-723.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, 
Smith DC, McDermott DF, Powderly JD, Carvajal 
RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, 
Antonia SJ, et al. Safety, activity, and immune correlates 
of anti-PD-1  antibody in cancer. N Engl J Med. 2012; 
366:2443-2454.
4. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi 
NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, 
Reed K, Burke MM, Caldwell A, Kronenberg SA, et al. 
Nivolumab plus ipilimumab in advanced melanoma. N Engl 
J Med. 2013; 369:122-133.
5. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, 
Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, 
Oncotarget27751www.impactjournals.com/oncotarget
and T(regs) in the melanoma tumor microenvironment 
is driven by CD8(+) T cells. Sci Transl Med. 2013; 
5:200ra116.
6. Taube JM, Anders RA, Young GD, Xu H, Sharma R, 
McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian 
SL, Chen L. Colocalization of inflammatory response with 
B7-h1 expression in human melanocytic lesions supports 
an adaptive resistance mechanism of immune escape. Sci 
Transl Med. 2012; 4:127ra137.
7. Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, 
Kim YJ. Preclinical evidence that PD1 blockade cooperates 
with cancer vaccine TEGVAX to elicit regression of estab-
lished tumors. Cancer Res. 2014; 74:4042-4052.
8. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella 
C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, 
Nixon DF, Bhardwaj N. Rapid generation of broad T-cell 
immunity in humans after a single injection of mature den-
dritic cells. J Clin Invest. 1999; 104:173-180.
9. Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, 
Hellmich M, Engert A, von Bergwelt-Baildon M. Dendritic 
cell based tumor vaccination in prostate and renal cell can-
cer: a systematic review and meta-analysis. PLoS One. 
2011; 6:e18801.
10. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, 
Sette A, Rosenberg SA, Kawakami Y. Improved induction 
of melanoma-reactive CTL with peptides from the mela-
noma antigen gp100 modified at HLA-A*0201-binding 
residues. J Immunol. 1996; 157:2539-2548.
11. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, 
Clarke MR, Lotze MT, Storkus WJ. Therapy of murine 
tumors with tumor peptide-pulsed dendritic cells: depen-
dence on T cells, B7 costimulation, and T helper cell 
1-associated cytokines. The Journal of experimental medi-
cine. 1996; 183:87-97.
12. von Andrian UH, Mempel TR. Homing and cellular traffic 
in lymph nodes. Nat Rev Immunol. 2003; 3:867-878.
13. Tretter T, Venigalla RK, Eckstein V, Saffrich R, Sertel 
S, Ho AD, Lorenz HM. Induction of CD4+ T-cell anergy 
and apoptosis by activated human B cells. Blood. 2008; 
112:4555-4564.
14. Tu W, Lau YL, Zheng J, Liu Y, Chan PL, Mao H, Dionis 
K, Schneider P, Lewis DB. Efficient generation of human 
alloantigen-specific CD4+ regulatory T cells from naive 
precursors by CD40-activated B cells. Blood. 2008; 
112:2554-2562.
15. Kleindienst P, Brocker T. Concerted antigen presentation 
by dendritic cells and B cells is necessary for optimal CD4 
T-cell immunity in vivo. Immunology. 2005; 115:556-564.
16. Parekh VV, Prasad DV, Banerjee PP, Joshi BN, Kumar A, 
Mishra GC. B cells activated by lipopolysaccharide, but not 
by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T 
cells: role of TGF-beta 1. J Immunol. 2003; 170:5897-5911.
17. Shimabukuro-Vornhagen A, Kondo E, Liebig T, von 
Bergwelt-Baildon M. Activated human B cells: stimulatory 
or tolerogenic antigen-presenting cells? Blood. 2009; 
114:746-747; author reply 747.
18. Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. 
Long-term human B cell lines dependent on interleukin-4 
and antibody to CD40. Science. 1991; 251:70-72.
19. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung 
K, Daley J, Delgado JC, Gribben JG, Nadler LM. CD40-
activated human B cells: An alternative source of highly 
efficient antigen presenting cells to generate autologous 
antigen-specific T cells for adoptive immunotherapy. J Clin 
Invest. 1997; 100:2757-2765.
20. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, 
Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, 
Wucherpfennig KW, Nadler LM, Schultze JL. Human pri-
mary and memory cytotoxic T lymphocyte responses are 
efficiently induced by means of CD40-activated B cells as 
antigen-presenting cells: potential for clinical application. 
Blood. 2002; 99:3319-3325.
21. Wiesner M, Zentz C, Mayr C, Wimmer R, Hammerschmidt 
W, Zeidler R, Moosmann A. Conditional immortalization of 
human B cells by CD40 ligation. PLoS One. 2008; 3:e1464.
22. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau 
J, Hwu P. CD40-stimulated B lymphocytes pulsed with 
tumor antigens are effective antigen-presenting cells 
that can generate specific T cells. Cancer Res. 2003; 
63:2836-2843.
23. Shen S, Xu Z, Qian X, Ding Y, Yu L, Liu B. Autogeneic 
rna-electroporated CD40-ligand activated b-cells from hepa-
tocellular carcinoma patients induce CD8+ T-cell responses 
ex vivo. Experimental oncology. 2007; 29:137-143.
24. von Bergwelt-Baildon M, Schultze JL, Maecker B, Menezes 
I, Nadler LM. Correspondence re R. Lapointe et al., CD40-
stimulated B lymphocytes pulsed with tumor antigens are 
effective antigen-presenting cells that can generate specific 
T cells. Cancer Res 2003;63:2836-43. Cancer Res. 2004; 
64:4055-4056; author reply 4056-4057.
25. Wu C, Liu Y, Zhao Q, Chen GM, Chen JH, Yan XM, Zhou 
YH, Huang ZH. Soluble CD40 ligand-activated human 
peripheral B cells as surrogated antigen presenting cells: A 
preliminary approach for anti-HBV immunotherapy. Virol 
J. 2010; 7.
26. Klein-Gonzalez NK, Wennhold K, Balkow S, Kondo E, 
Bolck B, Weber T, Garcia-Marquez M, Grabbe S, Bloch 
W, von Bergwelt-Baildon M, Shimabukuro-Vornhagen 
A. In vitro and in vivo imaging of initial B-T-cell interac-
tions in the setting of B-cell based cancer immunotherapy. 
Oncoimmunology. 2015; 4:e1038684.
27. von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, 
Popov A, Klein-Gonzalez N, Fiore F, Debey S, Draube A, 
Maecker B, Menezes I, Nadler LM, Schultze JL. CD40-
activated B cells express full lymph node homing triad and 
induce T-cell chemotaxis: potential as cellular adjuvants. 
Blood. 2006; 107:2786-2789.
Oncotarget27752www.impactjournals.com/oncotarget
28. Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, Li S, Chang 
AE. Adoptive transfer of tumor reactive B cells confers host 
T-cell immunity and tumor regression. Clin Cancer Res. 
2011; 17:4987-4995.
29. Mason NJ, Coughlin CM, Overley B, Cohen JN, Mitchell 
EL, Colligon TA, Clifford CA, Zurbriggen A, Sorenmo 
KU, Vonderheide RH. RNA-loaded CD40-activated B cells 
stimulate antigen-specific T-cell responses in dogs with 
spontaneous lymphoma. Gene therapy. 2008; 15:955-965.
30. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor 
TP, Vonderheide RH, Mason NJ. CD40-activated B cell 
cancer vaccine improves second clinical remission and 
survival in privately owned dogs with non-Hodgkin’s lym-
phoma. PLoS One. 2011; 6:e24167.
31. Garcia-Marquez MA, Shimabukuro-Vornhagen A, 
Theurich S, Kochanek M, Weber T, Wennhold K, Dauben 
A, Dzionek A, Reinhard C, von Bergwelt-Baildon M. A 
multimerized form of recombinant human CD40 ligand 
supports long-term activation and proliferation of B cells. 
Cytotherapy. 2014; 16:1537-1544.
32. Sallusto F, Lanzavecchia A. Efficient presentation of solu-
ble antigen by cultured human dendritic cells is maintained 
by granulocyte/macrophage colony-stimulating factor plus 
interleukin 4 and downregulated by tumor necrosis fac-
tor alpha. The Journal of experimental medicine. 1994; 
179:1109-1118.
33. Shortman K, Liu YJ. Mouse and human dendritic cell sub-
types. Nat Rev Immunol. 2002; 2:151-161.
34. Barrou B, Benoit G, Ouldkaci M, Cussenot O, Salcedo 
M, Agrawal S, Massicard S, Bercovici N, Ericson ML, 
Thiounn N. Vaccination of prostatectomized prostate can-
cer patients in biochemical relapse, with autologous den-
dritic cells pulsed with recombinant human PSA. Cancer 
Immunol Immunother. 2004; 53:453-460.
35. Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor 
Straten P, Andersen MH, Pedersen AE, Claesson MH, 
Lorentzen T, Johansen JS, Svane IM. Therapeutic den-
dritic cell vaccination of patients with metastatic renal cell 
carcinoma: a clinical phase 1/2 trial. J Immunother. 2008; 
31:771-780.
36. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. 
Dendritic cells injected via different routes induce immu-
nity in cancer patients. J Immunol. 2001; 166:4254-4259.
37. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, 
Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. 
Autologous dendritic cells transfected with prostate-specific 
antigen RNA stimulate CTL responses against metastatic 
prostate tumors. J Clin Invest. 2002; 109:409-417.
38. Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, 
Niedermann G, Giesler JM, Juttner E, Peters JH, Haring B, 
Leo R, Unger C, Azemar M. Immunotherapy of patients 
with hormone-refractory prostate carcinoma pre-treated 
with interferon-gamma and vaccinated with autologous 
PSA-peptide loaded dendritic cells--a pilot study. The 
Prostate. 2007; 67:500-508.
39. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser 
M, Hammerstad H, Waehre H, Raabe N, Gaudernack G. 
Immunotherapy with allotumour mRNA-transfected den-
dritic cells in androgen-resistant prostate cancer patients. 
British journal of cancer. 2005; 93:749-756.
40. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, 
Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger 
D, Foster C, Szczepiorkowski ZM, Webber SM, et al. 
Clinical and immunologic effects of intranodal autolo-
gous tumor lysate-dendritic cell vaccine with Aldesleukin 
(Interleukin 2) and IFN-{alpha}2a therapy in metastatic 
renal cell carcinoma patients. Clin Cancer Res. 2009; 
15:4986-4992.
41. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, 
Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, Vieweg 
J. Telomerase mRNA-transfected dendritic cells stimu-
late antigen-specific CD8+ and CD4+ T cell responses in 
patients with metastatic prostate cancer. J Immunol. 2005; 
174:3798-3807.
42. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von 
Moos R, Bohme C, Schmid HP, Ackermann D, Cerny 
T, Ludewig B, Groettrup M, Gillessen S. Dendritic cell-
based multi-epitope immunotherapy of hormone-refrac-
tory prostate carcinoma. Cancer Immunol Immunother. 
2006; 55:1524-1533.
43. Wei YC, Sticca RP, Li J, Holmes LM, Burgin KE, 
Jakubchak S, Bouton-Verville H, Williamson J, Meyer K, 
Evans L, Martin J, Stephenson JJ, Trocha S, et al. Combined 
treatment of dendritoma vaccine and low-dose interleukin-2 
in stage IV renal cell carcinoma patients induced clinical 
response: A pilot study. Oncol Rep. 2007; 18:665-671.
44. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa 
MV, Valone FH. Immunotherapy of hormone-refractory 
prostate cancer with antigen-loaded dendritic cells. J Clin 
Oncol. 2000; 18:3894-3903.
45. Lee J, Dollins CM, Boczkowski D, Sullenger BA, Nair 
S. Activated B cells modified by electroporation of mul-
tiple mRNAs encoding immune stimulatory molecules are 
comparable to mature dendritic cells in inducing in vitro 
antigen-specific T-cell responses. Immunology. 2008; 
125:229-240.
46. Guo S, Xu J, Denning W, Hel Z. Induction of protective 
cytotoxic T-cell responses by a B-cell-based cellular vac-
cine requires stable expression of antigen. Gene therapy. 
2009; 16:1300-1313.
47. Neron S, Racine C, Roy A, Guerin M. Differential 
responses of human B-lymphocyte subpopulations to 
graded levels of CD40-CD154 interaction. Immunology. 
2005; 116:454-463.
48. Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe 
A, Kochanek M, von Bergwelt-Baildon MS. The immu-
nosuppressive factors IL-10, TGF-beta, and VEGF do not 
affect the antigen-presenting function of CD40-activated B 
cells. J Exp Clin Cancer Res. 2012; 31:47.
Oncotarget27753www.impactjournals.com/oncotarget
49. Opal SM. Endotoxins and other sepsis triggers. 
Contributions to nephrology. 2010; 167:14-24.
50. Rodriguez-Pinto D, Moreno J. B cells can prime naive 
CD4+ T cells in vivo in the absence of other professional 
antigen-presenting cells in a CD154-CD40-dependent man-
ner. Eur J Immunol. 2005; 35:1097-1105.
51. Batista FD, Neuberger MS. Affinity dependence of the 
B cell response to antigen: a threshold, a ceiling, and the 
importance of off-rate. Immunity. 1998; 8:751-759.
52. Tasian SK, Gardner RA. CD19-redirected chimeric antigen 
receptor-modified T cells: a promising immunotherapy for 
children and adults with B-cell acute lymphoblastic leuke-
mia (ALL). Therapeutic advances in hematology. 2015; 
6:228-241.
53. Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani 
H, Ahmed AR. A review of the current use of rituximab in 
autoimmune diseases. International immunopharmacology. 
2009; 9:10-25.
54. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo 
T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase 
of tumor rejection by T cell receptor (TCR) transgenic 
CD8+ T cells. Cancer Res. 2004; 64:1140-1145.
55. Liebig TM, Fiedler A, Klein-Gonzalez N, Shimabukuro-
Vornhagen A, von Bergwelt-Baildon M. Murine model 
of CD40-activation of B cells. J Vis Exp. 2010; doi: 
10.3791/1734.
